Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

Condition:   Metastatic Hormone-Sensitive Prostate Cancer
Interventions:   Biological: PROSTVAC-V;   Biological: PROSTVAC-F;   Drug: Nivolumab;   Drug: Ipilimumab;   Biological: Neoantigen DNA vaccine;   Device: TriGrid Delivery System;   Procedure: Tumor biopsy;   Procedure: Peripheral blood;   Procedure: Fecal samples;   Procedure: Leukapheresis
Sponsors:   Washington University School of Medicine;   Bristol-Myers Squibb;   Prostate Cancer Foundation;   BJH Foundation;   Bavarian Nordic
Recruiting